London-listed MaxCyte releases terms for U.S. IPO, valuing biotech firm at up to $1.3B
Pogonici/iStock via Getty Images
- MaxCyte Inc. (MXCT) released details Monday for a planned U.S. IPO that will make the biotech dual-listed in New York and London while valuing the firm at up to $1.3B.
- The company wrote in a revised S-1 filing with the U.S….
